Clovis Oncology (CLVS) Defended at SunTrust

Credit Suisse Sees Up to a $7 Cut in Target Price to Clovis (CLVS) if Platinum Resistant/Refractory Removed; M&A Thesis Intact

Credit Suisse analyst Kennen MacKay reiterated an Outperform rating and $41 price target on Clovis Oncology (NASDAQ: CLVS) after the company presented data from their NDA submission package in 3L+ BRCA+ ovarian cancer. The 0% ORR in platinum-refractory patients and 25% ORR in platinum-resistant patients were disappointing,... More

Clovis (CLVS): Solid Treatment Choice but Maintenance Use Seems Unlikely - Stifel

Stifel analyst Thomas Shrader reiterated a Buy rating and $45 price target on Clovis Oncology (NASDAQ: CLVS) following data at ESMO 2016 that probably had only two new numbers: a 25% response rate in Pt-resistant patients and a 0% response rate in Pt-refractory patients.

Shrader commented, "These numbers are slightly lower than the... More

Clovis Oncology (CLVS) Bounces Off Lows, Remains Down 13.8%

Clovis Oncology (NASDAQ: CLVS) is bouncing off earlier lows as analysts at Piper Jaffray defend the name following this morning's data which was sub-par to a competitor's. Shares are up 13.8% after trading down nearly 30% earlier.

Clovis Oncology (CLVS) Announces Presentation of Encouraging Efficacy, Safety Data on Rucaparib in BRCA Ovarian Cancer

Clovis Oncology (Nasdaq: CLVS) announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen. Rucaparib is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations who have been treated with two or more chemotherapies, and the submission has a PDUFA date of February 23, 2017.

Rucaparib is the Companys oral, small molecule inhibitor of PARP1, PARP2 and PARP3 currently being developed for the... More